Metabolic Syndrome and Contrast Induced Nephropathy
- Conditions
- Contrast Induced NephropathyMetabolic Syndrome
- Registration Number
- NCT02192372
- Lead Sponsor
- Ankara University
- Brief Summary
Prevention of contrast induced nephropathy after interventional cardiologic procedures deserves close interest because of its association with prolonged hospitalization, increased cost and increased in hospital and long term mortality rates. An observational prospective cohort study was designed to determine whether metabolic syndrome predicts the development of contrast induced nephropathy after elective percutaneous coronary intervention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 599
Patients must be scheduled for elective percutaneous coronary intervention Clinical diagnosis of metabolic syndrome Patients must give informed consent
Acute coronary events Acute renal failure End stage renal failure requiring hemodialysis Contrast allergy and exposure to nephrotoxic agent within 1 week before percutaneous coronary intervention Exposure to contrast agent within 1 week before the procedure.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Contrast induced nephropathy 24-48 hours after the percutaneous coronary intervention Contrast induced nephropathy was defined as an increase in serum creatinine of \>25% or \>0.5 mg/dl above the baseline value 24 or 48 hours after angiography.
- Secondary Outcome Measures
Name Time Method glomerular filtration rate 48 hours after the percutaneous coronary intervention Glomerular filtration rate was estimated using the Cockcroft-Gault formula: (140-age) x weight (kg)/ serum creatinine (mg/dl) x 72 (x 0.85 for females)
Trial Locations
- Locations (1)
Ankara University School Of Medicine, Department of Cardiology
🇹🇷Ankara, Turkey